During neoadjuvant chemotherapy, the KRAS ctDNA levels significantly decreased: at four weeks, a total of 63% of patients with KRAS-mutated tumours had detectable ctDNA, while this dropped to 19% of patients preoperatively (p = 0.0001). The gene discussed is KRAS; the disease is neoplasm.